natgillin/translations-raw huggingface dataset:
The use according to Claim 13, wherein the additional therapeutic agent is selected from the group consisting of lamivudine, adefovir, tenofovir, telbivudine, entecavir, interferon alpha-2b, pegylated interferon alpha-2a, interferon alpha 2a, interferon alpha N1, prednisone, predinisolone, Thymalfasin®, retinoic acid receptor agonists, 4-methylumbelliferone, Alamifovir®, Metacavir®, Albuferon®, cytokines and agonists of TLRs. 
Spoj ili kompozicija za uporabu prema patentnom zahtjevu 27, naznačeni time što je dodatno terapeutski sredstvo izabrano iz grupe koju čine lamivudin, adefovir, tenofovir, telbivudin, entekavir, interferon alfa-2b, pegilirani interferon alfa-2a, interferon alfa 2a, interferon alfa N1, prednizon, prednizolon, Timalfasin®, agonisti receptora za retinoevu kiselinu, 4-metilumbeliferon, Alamifovir®, Metacavir®, Albuferon®, citokini i agonisti TLRs.
combining the cellulose fibres of step a) and the at least one filler of step b); 
kombiniranja celuloznih vlakana iz koraka a) i barem jednog punila i/ili pigmenta iz koraka b);
fibrillating the cellulose fibres in an aqueous environment in the presence of the at least one filler from step c) until a nano-fibrillar gel is formed, wherein the formation of the gel is verified by monitoring the viscosity of the mixture in dependence of the shearing rate, wherein the viscosity decrease of the mixture upon step-wise increase of the shearing rate is larger than the corresponding viscosity increase upon subsequent step-wise reduction of the shearing rate over at least part of the shear rate range as shearing approaches zero; providing additional non-fibrillated fibres in the form of a fibre web; combining the gel of step d) with the non-fibrillated fibres in the form of a fibre web of step e) 
fibrilacije celuloznih vlakana u prisutnosti barem jednog punila i/ili pigmenta sve dok nema preostalih vlakana i stvaranje nano-vlaknastog gela samo sa primarnim vlaknima u vodenom okruženju, pri čemu se stvaranje gela provjerava promatranjem viskoznosti smjese u ovisnosti o brzini smicanja, pri čemu se viskoznost smjese smanjuje nakon što je stepeničasto povećanje brzine smicanja veće od odgovarajućeg povećanja viskoznosti poslije naknadnog stepeničastog smanjenja brzine smicanja tijekom barem dijela raspona brzine smicanja dok se smicanje približava nuli; osiguravanja dodatnih ne-fibriliranih vlakana; miješanja gela iz koraka d) sa vlaknima iz koraka c).
The process according to any one of the preceding claims, characterized in that the filler of step b) is selected from the group comprising precipitated calcium carbonate (PCC), natural ground calcium carbonate (GCC), surface modified calcium carbonate; dolomite; talc; bentonite; clay; magnesite; satin white; sepiolite, huntite, diatomite; silicates; and mixtures thereof; and preferably is selected from the group of precipitated calcium carbonate having vateritic, calcitic or aragonitic crystal structure, especially ultrafine discrete prismatic, scalenohedral or rhombohedral precipitated calcium carbonate; natural ground calcium carbonate being selected from marble, limestone and/or chalk; and mixtures thereof. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je punilo i/ili pigment iz koraka b) odabran iz skupine koja sadrži taložni kalcijev karbonat (PCC), prirodni usitnjeni kalcijev karbonat (GCC), površinski izmijenjeni kalcijev karbonat; dolomit; talk; bentonit; glinu; magnezit; bijeli satin; sepiolit, huntit, dijatomit; silikate; i njihove mješavine; te je poželjno odabran iz skupine koja sadrži taložni kalcijev karbonat koji ima vateritnu, kalcitnu ili aragonitnu kristalnu strukturu, naročito ultrafini diskretni prizmatični, skalenohedralni ili rombohedralni taložni kalcijev karbonat; prirodni usitnjeni kalcijev karbonat koji je odabran od mramora, vapnenca i/ili krede; te njihove mješavine.
The process according to any one of the preceding claims, characterized in that before, during or after the addition of further fibres in step e), but after step d) and before step f), at least one further filler is added, which is preferably selected from the group comprising precipitated calcium carbonate; natural ground calcium carbonate; surface modified calcium carbonate; dolomite; talc; bentonite; clay; magnesite; satin white; sepiolite, huntite, diatomite; silicates; and mixtures thereof; and preferably is selected from the group of precipitated calcium carbonate having vateritic, calcitic or aragonitic crystal structure, especially ultrafine discrete prismatic, scalenohedral or rhombohedral precipitated calcium carbonate; natural ground calcium carbonate being selected from marble, limestone and/or chalk; and mixtures thereof. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da se prije, tijekom ili poslije dodavanja dodanih vlakana u koraku e), ali poslije koraka d) i prije koraka f), dodaje barem jedno dodatno punilo i/ili pigment, koje je poželjno odabrano iz skupine koja sadrži taložni kalcijev karbonat; prirodni usitnjeni kalcijev karbonat; površinski izmijenjeni kalcijev karbonat; dolomit; talk; bentonit; glinu; magnezit; bijeli satin; sepiolit, huntit, dijatomit; silikate; i njihove mješavine; te je poželjno odabrano iz skupine koja sadrži taložni kalcijev karbonat koji ima vateritnu, kalcitnu ili aragonitnu kristalnu strukturu, naročito ultrafini diskretni prizmatični, skalenohedralni ili rombohedralni taložni kalcijev karbonat; prirodni usitnjeni kalcijev karbonat koji je odabran od mramora, vapnenca i/ili krede; te njihove mješavine.
A system for closing a glass door which is supported by a floor, the door being movable between an open position and a closed position, the system comprising: 
Spojnica za zatvaranje vrata, poželjno staklenih vrata, koju podupire stacionarna potporna struktura, vrata se pomiču između otvorenog položaja i zatvorenog položaja, spojnica za zatvaranje vrata obuhvaća:
System according to the preceding claim, wherein said at least one first front face (35", 36 ") and at least one first contact surface (37", 38 ") are substantially parallel to each other in said closed door position and substantially perpendicular to each other in said open door position, said at least one second front face (45 ") and at least one second contact surface (46 ") being substantially perpendicular to each other in said closed door position and substantially parallel to each other in said open door position. 
Spojnica za zatvaranje vrata prema zahtjevu 5, gdje su to barem jedno prvo prednje lice (35", 36") i barem jedna prva kontaktna površina (37", 38") u biti međusobno paralelni u zatvorenom položaju vrata i u biti međusobno okomiti u položaju otvorenih vrata, barem jedno drugo prednje lice (45") i barem jedna druga kontaktna površina (46") su u biti međusobno okomiti u zatvorenom položaju vrata i u biti međusobno paralelni u položaju otvorenih vrata.
A compound of the Formula: 
Spoj Formule II:
X represents chloro; and/or 
X predstavlja klor; i/ili
A process as claimed in any one of the preceding claims, wherein the molar ratio of the compounds of formula II and III in the process of the invention is about 1:1 and/or the molar equivalent of the titanium chloride compound to compound of formula II or III is 1.3:1. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je molarni omjer spojeva formula II i III u postupku izuma je oko 1:1 i/ili molarni ekvivalent spoja titanij klorida prema spoju formule II ili III je 1.3:1.
A process for the isolation/purification of a compound of formula I, as defined in Claim 1, which process comprises preparing a compound of formula I by the process of any one of Claims 1 to 4, followed by crystallisation or precipitation of the compound, in a solvent system. 
Postupak za izolaciju/ pročišćavanje spoja formule I, kao što je definiran u patentnom zahtjevu 1, koji postupak sadrži pripremu spoja formule 1 postupkom prema bilo kojem od patentnih zahtjeva 1 do 4, nakon čega slijedi kristalizacija ili precipitacija spoja, u sustavu otapala.
A process as claimed in Claim 5, wherein the solvent system comprises an alcohol, optionally mixed with water. 
Postupak prema patentnom zahtjevu 5, pri čemu sustav otapala sadrži alkohol, opcionalno pomiješan s vodom.
isolation of the compound of formula I obtained by step (ii) above according to a process claimed in Claim 5, Claim 6 or Claim 7. 
izoliranje spoja formule I dobivenog gornjim korakom (ii) prema postupku opisanom u patentnom zahtjevu 5, 6 ili 7.
A process for the preparation of a compound of formula I as defined in Claim 1 but in which R1 represents C1-6 alkyl terminally substituted with a -OH group, which comprises preparation of a compound of formula I in which R1 represents H followed by reaction with a compound of formula VII, X3-R1b-C(O)OR1c VII wherein X3 represents a suitable leaving group, R1b represents C1-5 alkyl, and R1c represents optionally substituted C1-6 alkyl, followed by reduction of the ester moiety to a -CH2-OH moiety. 
Postupak za pripravu spoja formule I kao što je definiran u patentnom zahtjevu 1 ali u kojem R1 predstavlja C1-6 alkil terminalno supstituiran sa -OH skupinom, koji sadrži pripremu spoja formule I u kojem R1 predstavlja H nakon čega slijedi reakcija spoja formule VII, -R1b-C(O)OR1c VII gdje X3 predstavlja prikladnu odlaznu skupinu, R1b predstavlja C1-5 alkil, te R1c predstavlja opcionalno supstituirani C1-6 alkil, nakon čega slijedi redukcija esternog dijela u -CH2-OH dio.
A process for the preparation of a pharmaceutical formulation as claimed in Claim 14, wherein the process is followed by the step of bringing into association the compound of formula I or salt thereof so formed, with one or more pharmaceutically-acceptable excipients, adjuvants, diluents or carriers. 
Postupak za pripravu farmaceutskog pripravka prema patentnom zahtjevu 14, pri čemu nakon postupka slijedi korak spajanja spoja formule I ili njegove soli nastalog postupkom, sa jednim ili više farmaceutski prihvatljivih ekscipijensa, adjuvansa, razrjeđivača ili nosača.
a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from 
C1-6 alkil-skupina opcijski supstituirana s 1 do 3 supstituenta odabrana od sljedećih:
is a C6-14 aryl group or a heterocyclic group, each of which is optionally substituted by 1 to 3 substituents selected from 
je C6-14 aril-skupina ili heterociklička skupina, od kojih je svaka opcijski supstituirana s 1 do 3 supstituenta odabrana od sljedećih:
is a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from 
je C1-6 alkil-skupina opcijski supstituirana s 1 do 3 supstituenta odabrana od sljedećih:
The pharmaceutical agent of claim 10, for use in the prophylaxis or treatment of diabetes or obesity. 
Farmaceutsko sredstvo prema zahtjevu 10, naznačeno time, da se upotrebljava za profilaksu ili liječenje dijabetesa ili pretilosti.
A compound or salt of claim 1, for use in the prophylaxis or treatment of diabetes or obesity. 
Spoj ili sol prema zahtjevu 1, naznačen time, da se upotrebljava za profilaksu ili liječenje dijabetesa ili pretilosti.
One or more oligomers of lactic acid for use in the prophylaxis and/or treatment of gynaecological infections by administering the one or more oligomers of lactic acid to the vagina, wherein the one or more oligomers of lactic acid has the following formula I wherein n is an integer from 2 to 25. 
Jedan ili više oligomera mliječne kiseline za uporabu u profilaksi i/ili liječenju ginekoloških infekcija administriranjem jednog ili više oligomera mliječne kiseline u vaginu, pri čemu jedan ili više oligomera mliječne kiseline ima slijedeću formulu I [image] gdje je n cijeli broj od 2 do 25.
One or more oligomers of lactic acid for use according to claim 1, wherein the infection is a bacterial infection. 
Jedan ili više oligomera mliječne kiseline za uporabu prema patentnom zahtjevu 1, pri čemu je infekcija bakterijska infekcija.
One or more oligomers of lactic acid for use according to claim 2, wherein the bacterial infection is selected from bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethtitis. 
Jedan ili više oligomera mliječne kiseline za uporabu prema patentnom zahtjevu 2, pri čemu je bakterijska infekcija odabrana od bakterijske vaginoze, nespecifičnog kolpitisa, senilnog kolpitisa, cervicitisa, i uretitisa.
One or more oligomers of lactic acid for use according to claim 1, wherein the infection is a viral infection. 
Jedan ili više oligomera mliječne kiseline za uporabu prema patentnom zahtjevu 1, pri čemu je infekcija virusna infekcija.
One or more oligomers of lactic acid for use according to claim 6, wherein the viral infection is selected from Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV). 
Jedan ili više oligomera mliječne kiseline za uporabu prema patentnom zahtjevu 6, pri čemu je virusna infekcija odabrana od Virusa Humane Imunodeficijencije (HIV), Virusa Herpes Simpleks (HSV), Humanog Papiloma Virusa (HPV).
One or more oligomers of lactic acid for use according to claim 1, wherein n is from 2 to 20, from 3 to 25, from 3 to 20, from 2 to 15, from 3 to 15, from 2 to 10, from 3 to 10, from 4 to 10, or from 4 to 9. 
Jedan ili više oligomera mliječne kiseline za uporabu prema patentnom zahtjevu 1, pri čemu je n od 2 do 20, od 3 do 25, od 3 do 20, od 2 do 15, od 3 do 15, od 2 do 10, od 3 do 10, od 4 do 10, ili od 4 do 9.
One or more oligomers of lactic acid for use according to any of the preceding claims, wherein the one or more oligomers of lactic acid is present in an oligomeric product having an average weight molecular weight of from about 300 to about 2,000. 
Jedan ili više oligomera mliječne kiseline za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je jedan ili više oligomera mliječne kiseline prisutan u oligomerskom proizvodu koji ima prosječnu masu molekularne mase od oko 300 do oko 2,000.
One or more oligomers of lactic acid for use according to any of the preceding claims, wherein the total concentration of the oligomers HL2, HL3, HL4 and HL5 is at least about 30% w/w, and wherein HL2 is the dimer of lactic acid, HL3 is the trimer of lactic acid, HL4 is the tetramer of lactic acid and HL5 is the pentamer of actic acid 
Jedan ili više oligomera mliječne kiseline za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je ukupna koncentracija oligomera HL2, HL3, HL, i HL5 barem oko 30% w/w, te pri čemu HL? je dimer mliječne kiseline, HL3 je trimer mliječne kiseline, HL, je tetramer mliječne kiseline i HL5 je pentamer mliječne kiseline
One or more oligomers of lactic acid for use according to any of the preceding claims, wherein the one or more oligomers of lactic acid release lactic acid over a time period of at least 8 hours, at least 12 hours, such as at least 16 hours, at least 20 hours, at least 24 hours, at least 36 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days when exposed to water at room temperature. 
Jedan ili više oligomera mliječne kiseline za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu jedan ili više oligomera mliječne kiseline otpuštaju mliječnu kiselinu kroz vremenski period od barem 8 sati, barem 12 sati, kao barem 16 sati, barem 20 sati, barem 24 sata, barem 36 sati, barem 2 dana, barem 3 dana, barem 4 dana, barem 5 dana, barem 6 dana, ili barem 7 dana kada su izloženi vodi pri sobnoj temperaturi.
One or more oligomers of lactic acid for use according to any of the preceding claims, wherein the one or more oligomers of lactic acid is comprised in a composition comprising from 0.02% to 100% w/w, from 0.1% to 95% w/w, from 1% to 96% w/w, from 5% to 95% w/w, from 10% to 90% w/w, from 15% to 90% w/w of the one or more oligomers of lactic acid. 
Jedan ili više oligomera mliječne kiseline za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je jedan ili više oligomera mliječne kiseline sadržan u pripravku koji sadrži od 0.02% do 100% w/w, od 0.1% do 95% w/w, od 1% do 96% w/w, od 5% do 95% w/w, od 10% do 90% w/w, od 15% do 90% w/w jednog ili više oligomera mliječne kiseline.
One or more oligomers of lactic acid for use according to any of the preceding claims, wherein the one or more oligomers of lactic acid is comprised in a composition in the form of a solid, semi-solid or liquid composition. 
Jedan ili više oligomera mliječne kiseline za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je jedan ili više oligomera mliječne kiseline sadržan u pripravku u obliku krutog, semi- krutog ili tekućeg pripravka.
One or more oligomers of lactic acid for use according to any of the preceding claims, wherein the one or more oligomers of lactic acid is comprised in a composition the form of a tampon, vagitorium, vaginal aerosol, vaginal cup, vaginal gel, vaginal insert, vaginal patch, vaginal ring, vaginal sponge, vaginal soppository, vaginal cream, vaginal emulsion, vaginal foam, vaginal lotion, vaginal ointment, vaginal powder; vaginal shampoo, vaginal solution, vaginal spray, vaginal suspension, vaginal tablet, vaginal rod, vaginal shaum, vaginal disc, semipermeable packaging and any combination thereof. 
Jedan ili više oligomera mliječne kiseline za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je jedan ili više oligomera mliječne kiseline sadržan u pripravku u obliku tampona, vagitorija, vaginalnog aerosola, vaginalne šalice, vaginalnog gela, vaginalnog inserta, vaginalnog flastera, vaginalnog prstena, vaginalne spužve, vaginalnog čepića, vaginalne kreme, vaginalne emulzije, vaginalne pjene, vaginalnog losiona, vaginalne pomasti, vaginalnog pudra; vaginalnog šampona, vaginalne otopine, vaginalnog spreja, vaginalne suspenzije, vaginalne tablete, vaginalnog štapića, vaginalnog šauma, vaginalnog diska, semipropusnog materijala ili bilo koje kombinacije istih.
A pharmaceutical composition comprising one or more oligomers of lactic acid as defined in any of claims 1-22 together with a pharmaceutically acceptable excipient, the composition being in the form of a a tampon, vagitorium, vaginal aerosol, vaginal cup, vaginal gel, vaginal, insert, vaginal patch, vaginal ring, vaginal sponge, vaginal suppository, vaginal cream, vaginal emulsion, vaginal foam, vaginal lotion, vaginal ointment, vaginal powder, vaginal shampoo, vaginal solution, vaginal spray, vaginal suspension, vaginal tablet, vaginal rod, vaginal shaum, vaginal disc vaginal semipermeable packaging and any combinatiön thereof. 
Farmaceutski pripravak koji sadrži jedan ili više oligomera mliječne kiseline kao što je definirano u bilo kojem od patentnih zahtjeva 1-22, zajedno sa farmaceutski prihvatljivim ekscipijensom, pri čemu je pripravak u obliku tampona, vagitorija, vaginalnog aerosola, vaginalne šalice, vaginalnog gela, vaginalnog inserta, vaginalnog flastera, vaginalnog prstena, vaginalne spužve, vaginalnog čepića, vaginalne kreme, vaginalne emulzije, vaginalne pjene, vaginalnog losiona, vaginalne pomasti, vaginalnog pudra; vaginalnog šampona, vaginalne otopine, vaginalnog spreja, vaginalne suspenzije, vaginalne tablete, vaginalnog štapića, vaginalnog šauma, vaginalnog diska, semipropusnog materijala ili bilo koje kombinacije istih.
A pharmaceutical composition according to claim 23, wherein the pharmaceutically acceptable excipient is selected from the group consisting hydroxypropyl methylcellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyyl cellulose, ethyl hydroxyethyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, moderately cross-linked starch, acrylic polymers; polyethylene oxide, chitosan; and natural polymers. 
Farmaceutski pripravak prema patentnom zahtjevu 23, pri čemu je farmaceutski prihvatljivi ekscipijens odabran iz skupine koje se sastoji od hidroksipropil metilceluloze, metil celuloze, hidroksietil celuloze, hidroksipropil celutoze, etil hidroksietil celuloze, karboksimetil celuloze, natril karboksimetil celuloze, umjereno križno-povezanog škroba, akriličnih polimera; polietilen oksida, kitosana; i prirodnih polimera.
A pharmaceutical composition according to claim 23, wherein the oligomeric lactic acid contains: 
Farmaceutski pripravak prema patentnom zahtjevu 23, pri čemu oligomerna mliječna kiselina sadrži:
A pharmaceutical composition according to claim 23, wherein the oligomeric lactic acid contains: to 15% w/w of a lactic acid dimer; to 15% w/w of a lactic acid trimer; 
Farmaceutski pripravak prema patentnom zahtjevu 23, pri čemu oligomerna mliječna kiselina sadrži: 15% w/w dimera mliječne kiseline; 15% w/w trimera mliječne kiseline;
A prestretched polyethylene film having a longitudinal stretch ratio of from about 1:2 to about 1:4 and having a longitudinal elongation capability of at least 170 %, said elongation capability comprising an elastic component. 
Prethodno rastegnuta polietilenska folija koja sadrži linearni polietilen niske gustoće, ta prethodno rastegnuta folija ima longitudinalni omjer rastezanja od oko 1:2 do oko 1:4 i ima sposobnost longitudinalnog produljenja od najmanje 190%, ta sposobnost produljenja obuhvaća elastičnu komponentu.
A prestretched film according to claim 1, having a stretch ratio of about 1:2.5. 
Prethodno rastegnuta folija prema zahtjevu 1, ima omjer rastezanja od oko 1:2.5.
A prestretched film according to claim 3, having a content of LLDPE in the range of 60-99.9 % by weight and a content of LDPE in the range of 0.1-20 % by weight. 
Prethodno rastegnuta folija prema zahtjevu 3, ima sadržaj LLDPE-a u rasponu od 60-99.9% težine i sadržaj LDPE-a u rasponu od 0.1-20% težine.
compressing bulk material in a chamber to form a bale of compressed bulk material; 
komprimiranje rasutog (bulk) materijala u komori radi formiranja bale rasutog (bulk) materijala;
applying said film under tension around said bale, in direct contact with the compressed bulk material; and 
nanošenje te napete folije oko bale, u izravnom doticaju s komprimiranim rasutim (bulk) materijalom; i
wrapping said film under tension at least 1.5 turns around said bale, wherein substantially no expansion of the bale of compressed bulk material occurs when the bale is removed from the chamber. 
omatanje te napete folije najmanje 1.5 puta oko bale, gdje u biti ne dolazi do ekspanzije bale komprimiranog rasutog (bulk) materijala kada se bala makne iz komore.
A method according to any one of the claims 8 to 11, wherein 2-10 layers of said prestretched film are applied around the bale of compressed bulk material, as measured centrally on an envelope surface of the bale of compressed bulk material. 
Postupak prema bilo kojem od zahtjeva 8 do 11, gdje se 2-10 slojeva te prethodno rastegnute folije nanose oko bale komprimiranog rasutog (bulk) materijala, mjereno centralno na omotnoj površini bale komprimiranog rasutog (bulk) materijala.
A seismic clip as set forth in claim 1, wherein said lanced tab (43) has an upper edge (47) at an elevation equal to an elevation of an upper edge (42) of the adjacent opposed tab (39). 
Seizmička spajalica kako je određena prethodno u patentnom zahtjevu 1, pri čemu navedena isturena pločica (43) ima gornji rub (47) na povišenju jednakom povišenju gornjeg ruba (42) susjedne nasuprotne pločice (39).
A seismic clip as set forth in claim 1, wherein the lanced tab (43) is spaced from the plane of the wings by a distance of about 1,9 cm. 
Seizmička spajalica kako je određena prethodno u patentnom zahtjevu 1, pri čemu je isturena pločica (43) razmaknuta od ravnine krila s udaljenošću od približno 1,9 cm.
Pharmaceutical container according to claim 6, wherein the container is a syringe, vial, infusion bottle, ampoule, carpoule, a syringe equipped with a needle protection system, or a carpoule within an injection pen. 
Farmaceutski spremnik prema zahtjevu 6, gdje je spremnik štrcaljka, bočica, boca za infuziju, ampula, karpula, štrcaljka sa zaštitom igle ili karpula unutar injekcijske brizgalice (pen).
Process for preparing an aqueous preparation according to claim 8, wherein the aqueous preparation is diluted 1:2 to 1:8. 
Postupak pripreme vodenog pripravka prema zahtjevu 8, gdje je vodeni pripravak razrijeđen 1:2 do 1:8.